Targeting the lung by using MPO inhibitors or HOCl scavengers may prove to be effective to prevent the contribution of pulmonary neutrophilic inflammation towards systemic inflammation, the leading cause of obesity-associated metabolic abnormalities (Figure 2). The gene discussed is MPO; the disease is obesity due to melanocortin 4 receptor deficiency.